Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments

NICE has produced a resource impact template that incorporates the following technology appraisal guidance for relapsed and refractory multiple myeloma after 3 or more treatments:

• Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2025) NICE technology appraisal guidance 1114
• Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2024) NICE technology appraisal guidance 1023
• Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (2024) NICE technology appraisal guidance 1015
• Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments (2024) NICE technology appraisal guidance 970